Overview

SAR407899 Single-dose in Treatment of Mild to Moderate Erectile Dysfunction

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this clinical trial is to study the ability of SAR407899 to increase the duration of penile erection in male patients with mild-moderate Erectile Dysfunction. The secondary objectives of this clinical trial are to study the ability of SAR407899 to shorten increase the time to erection duration of penile erection in male patients with mild-moderate Erectile Dysfunction and to determine the overall safety and tolerability of SAR407899 in these patients.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Treatments:
Sildenafil Citrate